Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009;35(4):311-9.
doi: 10.1080/00926230902851322.

Effects of SNS activation on SSRI-induced sexual side effects differ by SSRI

Tierney K Ahrold  1 , Cindy M Meston
Affiliations
Randomized Controlled Trial

Effects of SNS activation on SSRI-induced sexual side effects differ by SSRI

Tierney K Ahrold et al. J Sex Marital Ther. 2009.

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are associated with significant sexual side effects. By definition, all SSRIs increase overall serotonin (5HT) by binding to serotonin autoreceptors (5HT(IA)); however, each SSRI has a unique portfolio of secondary binding properties to other neurotransmitters such as norepinephrine (NE). As 5HT(IA) receptors mediate NE neurotransmission, SSRIs that are highly selective for 5HT(IA) are more likely to reduce NE efficiency; however, in SSRIs that are less selective for 5HT(IA), this could be counteracted by secondary binding to NE. Norepinephrine is the major neurotransmitter of the sympathetic nervous system (SNS), which has been shown to mediate genital arousal in women; thus, it is possible that increasing SNS activity in women taking SSRIs that are highly selective for 5HT(IA) may counteract sexual side effects in those women. To test this hypothesis, we conducted a reanalysis of Meston (2004)'s 8-week, double-blind, cross-over, placebo-controlled study of the effects of ephedrine (50 mg taken 1 h prior to sexual activity) on self-reported sexual functioning of women taking paroxetine (N = 5), sertraline (N = 7), or fluoxetine (N = 7). As predicted, women taking SSRIs, which are highly selective for 5HT(IA) (sertraline, paroxetine), showed improvement in sexual arousal and orgasm. By contrast, women taking SSRIs, which are less selective for 5HT(IA) relative to NE (fluoxetine), showed no change or decrease in sexual functioning. These findings have implications for treating certain SSRI-induced sexual side effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Differential effects of ephedrine on sexual functioning in women taking sertraline, paroxetine, or fluoxetine, relative to placebo.
See this image and copyright information in PMC

References

    1. Balon R. SSRI-associated sexual dysfunction. American Journal of Psychiatry. 2006;163:1504–1509. - PubMed
    1. Beck AT, Beamesderfer A. Assessment of depression: The depression inventory. In: Pinchot P, editor. Modern problems in pharmacopsychiatry: Psychological measurements in psychopharmacology. Vol. 7. New York: Karger, Basel; 1974. pp. 151–169. - PubMed
    1. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW. Discontinuing or switching selective serotonin-reuptake inhibitors. The Annals of Pharmacotherapy. 2002;36:578–584. - PubMed
    1. Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. Journal of Affective Disorders. 2006;91:27–32. - PubMed
    1. Gitlin M. Sexual dysfunction with psychotropic drugs. Expert Opinion on Pharmacotherapy. 2003;4:2259–2269. - PubMed

Publication types

MeSH terms